Closed and semi-automated processing of CAR T cells

Product variability and manufacturing cost remain challenges in the widespread offering of CAR-T therapies to patients. In this application note, learn more about a robust end-to-end CAR-T cell therapy protocol for cGMP-compliant commercial manufacturing.

Go to the profile of RegMedNet
Jul 26, 2019
Page of
Go to the profile of RegMedNet


eCommunity, Future Science Group

RegMedNet is a networking site where users can share their knowledge and insights. This profile will share some content and updates from the RegMedNet team, including webinars, news and journal articles.

No comments yet.